Alternative production of Lead-203: Optimizing production, purification, and radiolabelling for enhanced theranostic applications
Our results support the use of <sup>203</sup>Pb produced using deuteron beam as valuable tools in the advancement of personalized nuclear medicine therapies. The high purity and specific activity of <sup>203</sup>Pb, achieved through dual Pb resin purification process, along with its effective radiolabelling with DOTATATE at high yield and long stability, underscore its potential for clinical use in diagnostic imaging, especially in neuroendocrine tumours.
Authors
- Etienne Nigron (ORCID: https://orcid.org/0000-0002-8265-8337)
- Maryne Tarinas
- Keerthana Kamalakannan
- Héloïse Dufour
- Arnaud Guertin (ORCID: https://orcid.org/0000-0002-9077-0994)
- Fabien Brelet
- Nicolas Bozovic
- Thomas Sounalet (ORCID: https://orcid.org/0000-0001-8884-9479)
- Rémy Dureau
- Nadia Audouin
- Férid Haddad (ORCID: https://orcid.org/0000-0001-6971-5969)
- A. Vidal
- Tony Prezeau
- Katalin Briand
- Lou Galichet
Institutions
- Centre National de la Recherche Scientifique (FR)
- Laboratoire de Physique Subatomique et des Technologies Associées (FR)
- Institut Génétique Nantes Atlantique (FR)
- IMT Atlantique (FR)
- Orano (France) (FR)
Publication Details
- Journal
- Nuclear Medicine and Biology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.nucmedbio.2025.109559
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00